Why Achillion Pharmaceuticals Stock Is Falling Today

Markets Motley Fool

What happened

Continue Reading Below

Shares of Achillion Pharmaceuticals (NASDAQ: ACHN) are falling hard today after the company announced that Johnson & Johnson (NYSE: JNJ) has decided to sell 18.4 million of the drugmaker's shares. This public offering represents all of J&J's holdings in the small-cap drugmaker, and it will reportedly not yield any proceeds for Achillion. As of 11:48 a.m. EST, Achillion stock is down by 11.92% on heavy volume on this news. 

So what

The timing of J&J's decision to dump its entire stake in Achillion is somewhat perplexing. Achillion, after all, just released positive early-stage data for its experimental kidney-disease treatment, ACH-4471, that could eventually be a big winner from a sales standpoint down the road. Apparently, J&J felt it was time to completely cut the cord after its hepatitis C development deal with Achillion fell apart due to the rapidly changing dynamics surrounding this shrinking market. 

Now what

With J&J calling it quits on its hepatitis C partnership with Achillion roughly two months ago, the drugmaker's core value proposition now revolves squarely around ACH-4471. While ACH-4471 is targeting a big market, the downside is that Achillion's lead drug candidate remains a few years away from producing results that could provide the basis for a regulatory filing. So, for now, investors may want to shy away from this falling knife. 

Continue Reading Below

10 stocks we like better than Achillion Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Achillion Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of November 6, 2017

George Budwell has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Johnson & Johnson. The Motley Fool has a disclosure policy.